Back to Search Start Over

Genetic scores to stratify risk of developing multiple islet autoantibodies and type 1 diabetes: A prospective study in children

Authors :
Andreas Beyerlein
Jin-Xiong She
Markus Hippich
Michael N. Weedon
Jan Krumsiek
Stephen S. Rich
Kendra Vehik
Richard A. Oram
Anette-G. Ziegler
Åke Lernmark
Marian Rewers
Andrea K. Steck
Christiane Winkler
Jeffrey P. Krischer
Brigitte I. Frohnert
Beena Akolkar
Michael Laimighofer
Ezio Bonifacio
Andrew T. Hattersley
William Hagopian
Jorma Toppari
Source :
PLoS Medicine, Vol 15, Iss 4, p e1002548 (2018), PLoS Med. 15:e1002548 (2018), PLoS Medicine
Publication Year :
2018
Publisher :
Public Library of Science (PLoS), 2018.

Abstract

Background Around 0.3% of newborns will develop autoimmunity to pancreatic beta cells in childhood and subsequently develop type 1 diabetes before adulthood. Primary prevention of type 1 diabetes will require early intervention in genetically at-risk infants. The objective of this study was to determine to what extent genetic scores (two previous genetic scores and a merged genetic score) can improve the prediction of type 1 diabetes. Methods and findings The Environmental Determinants of Diabetes in the Young (TEDDY) study followed genetically at-risk children at 3- to 6-monthly intervals from birth for the development of islet autoantibodies and type 1 diabetes. Infants were enrolled between 1 September 2004 and 28 February 2010 and monitored until 31 May 2016. The risk (positive predictive value) for developing multiple islet autoantibodies (pre-symptomatic type 1 diabetes) and type 1 diabetes was determined in 4,543 children who had no first-degree relatives with type 1 diabetes and either a heterozygous HLA DR3 and DR4-DQ8 risk genotype or a homozygous DR4-DQ8 genotype, and in 3,498 of these children in whom genetic scores were calculated from 41 single nucleotide polymorphisms. In the children with the HLA risk genotypes, risk for developing multiple islet autoantibodies was 5.8% (95% CI 5.0%–6.6%) by age 6 years, and risk for diabetes by age 10 years was 3.7% (95% CI 3.0%–4.4%). Risk for developing multiple islet autoantibodies was 11.0% (95% CI 8.7%–13.3%) in children with a merged genetic score of >14.4 (upper quartile; n = 907) compared to 4.1% (95% CI 3.3%–4.9%, P < 0.001) in children with a genetic score of ≤14.4 (n = 2,591). Risk for developing diabetes by age 10 years was 7.6% (95% CI 5.3%–9.9%) in children with a merged score of >14.4 compared with 2.7% (95% CI 1.9%–3.6%) in children with a score of ≤14.4 (P < 0.001). Of 173 children with multiple islet autoantibodies by age 6 years and 107 children with diabetes by age 10 years, 82 (sensitivity, 47.4%; 95% CI 40.1%–54.8%) and 52 (sensitivity, 48.6%, 95% CI 39.3%–60.0%), respectively, had a score >14.4. Scores were higher in European versus US children (P = 0.003). In children with a merged score of >14.4, risk for multiple islet autoantibodies was similar and consistently >10% in Europe and in the US; risk was greater in males than in females (P = 0.01). Limitations of the study include that the genetic scores were originally developed from case–control studies of clinical diabetes in individuals of mainly European decent. It is, therefore, possible that it may not be suitable to all populations. Conclusions A type 1 diabetes genetic score identified infants without family history of type 1 diabetes who had a greater than 10% risk for pre-symptomatic type 1 diabetes, and a nearly 2-fold higher risk than children identified by high-risk HLA genotypes alone. This finding extends the possibilities for enrolling children into type 1 diabetes primary prevention trials.<br />Anette-Gabriele Ziegler and colleagues report their novel genetic risk score for identifying infants with a high risk of developing type 1 diabetes.<br />Author summary Why was this study done? Prevention of childhood diseases such as type 1 diabetes is of medical importance. Prevention of type 1 diabetes might be best achieved by intervention prior to the development of islet autoantibodies, which define a pre-symptomatic disease stage. Early intervention requires tools such as measures of genetic risk that identify future cases. Risk for type 1 diabetes in the absence of a family history is currently identified by HLA genotyping, with maximum identified risk reaching around 5%. Genetic scores derived from multiple risk loci may improve risk stratification for pre-symptomatic type 1 diabetes. What did the researchers do and find? Two previously proposed genetic scores for type 1 diabetes risk were calculated for over 3,000 children without a family history of type 1 diabetes but with 1 of the 2 highest-risk HLA genotypes (heterozygous DR3 and DR4-DQ8 or homozygous DR4-DQ8) participating in the TEDDY cohort study, which prospectively follows children from birth for the development of islet autoantibodies and diabetes. We found that both of the genetic scores, and a merged genetic score that combined the features of both, stratified the risk for islet autoantibodies and diabetes in the children. The upper quartile of the merged genetic score was associated with a >10% risk for the pre-symptomatic stage of multiple islet autoantibodies, and almost half the children who developed pre-symptomatic or symptomatic diabetes were identified by this score. What do these findings mean? Combining genetic information from multiple risk loci can improve the prediction of diseases such as type 1 diabetes. A genetic risk score model is proposed that could be used to recruit infants into early type 1 diabetes primary prevention trials. The model provides a new paradigm for genetic screening and selection of at-risk infants that, together with family history and HLA genotyping, could identify up to 25% of future childhood cases of type 1 diabetes from less than 1% of newborns.

Details

Language :
English
ISSN :
15491676 and 15491277
Volume :
15
Issue :
4
Database :
OpenAIRE
Journal :
PLoS Medicine
Accession number :
edsair.doi.dedup.....b0d74a5ea54387d4ec8541a9d77e70c4